to take a little off the table!!!! the crazy
analyist have hyped a good solid company a little to
much....agn multiple now higher than most pure plays in
pharmaceuticals(exception being the ones thought to be in play),and
remember folks this aint no pure pharm play...the
derm,contact lens solution and medical device businesses do
not deserve anything close to 40 times 1999
eps....how about 15 or 20???....in any event,agn is a great
company long term ,but it isnt worth anything close to
by who's standard do you think is a fair
value...would like to see your model for valuation...not trying
to argue,but just would like to see how you value a
company like agn who has two non pharm pieces that
represent about 50% of their business,neither growing
much(lenscare down and surgical up less than 5%),in industry
sectors giving multipules less than 20 times 1999 eps
projections....agn pharm peers(like merck are now getting 40 times
1999 eps...i still think agn looks rich to
dont look now but coo is currently at 15.5 1999
concensus eps(1.50)....not that i am happy,but our whole
sector is under fire due to the ocular ssience
problem...in fact we have the highest multiple of anyone
else(wj is at 14 and ocular is now 10)...hopefully we can
get the street to find intrest in contact lens
companies in the future...lets all have fun and watch the
remarkable grouth of agn.
What are the basic criteria that a company uses
to decide whether to split their stock.
originally thought the AGN stock would've split when it
reached the $80's. Now it's over $100. What is AGN's
board waiting for?
Emsanet is a new Internet service provider.
Emsanet should be a profitable investment because;
Emsanet only charges $12 a month for service, has zero
debt, plans to be profitable before they go public, and
plans to pay dividends before they go public. Emsanet
is offering 1,000,000 shares of private stock at
three dollars and fifty cents a share. This is the
private offering price. The company plans to go public at
the beginning of 2000 at around $20 a share. As with
any investment this company does contain some risk.
This is a commission free transaction, with a minimum
investment of $3,500. For more information and an investor
package, contact investor relations toll free at (877)
387-3863 or email email@example.com . For return e-mails
please provide your mailing address and DAYTIME
TELEPHONE NUMBER. For more information US Funding visit
their web site at http://usfunding1.freeservers.com
Please serious inquiries only.
Restasis is cyclosporin for treatment of dry eye,
not infection. Check out Allergan annual report for
details. Currently only artificial tears are used for
symptoms. I know from experience dry eye is very
unpleasant. A dry eye patient's eyes are very sensitive.
won't know how big restasis can be until it is used
broadly in clinical practice. Side effects or tollerance
problems could show up in broad clinical use that wern't
seen in studies, if not, this could be BIG!